

RFK, Jr., CHD Call on FDA to Deny Emergency Use Authorization of Pfizer Vaccine for Infants and Children Under 5

By [Children's Health Defense](#)

Global Research, February 11, 2022

[Children's Health Defense](#) 10 February 2022

Region: [USA](#)

Theme: [Law and Justice](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch_crg](#).

Children’s Health Defense said it is poised to take legal action against the U.S. Food and Drug Administration’s vaccine advisory panel if the committee recommends Pfizer’s Emergency Use Authorization vaccine for children under 5.

Children’s Health Defense (CHD), along with Chairman and Chief Legal Counsel Robert F. Kennedy, Jr., today delivered [a letter](#) to top public health officials and the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) urging them to reject Pfizer’s application for Emergency Use Authorization (EUA) of its [COVID vaccine](#) for children 6 months through 4 years of age.

The letter reads, in part:

“We are writing to put you on notice that should you recommend this pediatric EUA vaccine to children under five years old, CHD is poised to take legal action against you.

“CHD will seek to hold you accountable for recklessly endangering this population with a product that has little, no, or even negative net efficacy but which may put them, without warning, at risk of many adverse health consequences, including [heart damage](#), stroke and other [thrombotic events](#) and reproductive harms.”

VRBPAC will meet Feb. 15 to consider [Pfizer’s](#) application for EUA status for this age group.

“There is absolutely no COVID emergency for children under 5 years old,” said CHD president and general counsel [Mary Holland](#). “Considering that healthy children have virtually [zero risk](#) of complications or death from COVID and that the [adverse events](#) being reported following COVID vaccination are at historic rates and climbing, it’s outrageous that the FDA is even discussing an EUA vaccine for this age group.”

The latest data from the U.S. government's Vaccine Adverse Event Reporting System shows a total of [1,088,560](#) reports of adverse events from all age groups following COVID vaccines. This includes [23,149 deaths](#) and [183,311 serious injuries](#) between Dec. 14, 2020, and Jan. 28, 2022.

Vaccine makers including Pfizer [cannot be held liable](#) for injuries and deaths following vaccination with EUA vaccines.

The letter to VRBPAC and health officials, including Centers for Disease Control and Prevention Director Dr. Rochelle Walensky and acting FDA Director Dr. Janet Woodcock, points out the following:

- A large [study](#) conducted in Germany showed zero deaths for children under 5 and a case fatality rate of three out of a million in children without comorbidities.
- A [Johns Hopkins study](#) monitoring 48,000 children diagnosed with COVID showed a zero mortality rate in children under 18 without comorbidities.
- A [study](#) in Nature demonstrated that children under 18 with no comorbidities have virtually no risk of death.
- [Data from England and Wales](#), published by the UK Office of National Statistics on January 17, 2022, revealed that throughout 2020 and 2021, only one child under the age of 5, without comorbidities, died from COVID in the two countries, whose total population is 60 million.
- [Another study](#) in Nature from April, suggests children's bodies clear the virus more easily than adults.
- [A study](#) published in December in Nature demonstrated how children efficiently mount effective, robust and sustained immune responses to COVID.

CHD this week asked the general public to also [contact VRBPAC and public health officials](#) with their concerns on granting EUA status for COVID vaccines targeting infants and young children.

"If the vaccine does attain EUA status, it will be an important milestone on the pharmaceutical industry's path to the ultimate goal of getting COVID shots on the federally-recommended childhood schedule," said Holland.

"This will then ensure immunity from liability for injuries and deaths in perpetuity to manufacturers and healthcare providers. Our children deserve better."

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @globalresearch_crg. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Children's Health Defense](#), [Children's Health Defense](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Children's Health
Defense](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca